JP5638007B2 - ベータ−アミロイド産生の減少のための二環式化合物 - Google Patents

ベータ−アミロイド産生の減少のための二環式化合物 Download PDF

Info

Publication number
JP5638007B2
JP5638007B2 JP2011546297A JP2011546297A JP5638007B2 JP 5638007 B2 JP5638007 B2 JP 5638007B2 JP 2011546297 A JP2011546297 A JP 2011546297A JP 2011546297 A JP2011546297 A JP 2011546297A JP 5638007 B2 JP5638007 B2 JP 5638007B2
Authority
JP
Japan
Prior art keywords
triazolo
phenyl
tetrahydro
amine
azepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011546297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515205A (ja
JP2012515205A5 (OSRAM
Inventor
ローレンス・アール・マーシン
ロリン・エイ・トンプソン・ザ・サード
ケネス・エム・ボーイ
ジェイソン・エム・ガーノン
メンディ・エイ・ヒギンス
ジアンリアン・シ
ヨン−ジン・ウ
ユンフイ・チャン
ジョン・イー・マコー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2012515205A publication Critical patent/JP2012515205A/ja
Publication of JP2012515205A5 publication Critical patent/JP2012515205A5/ja
Application granted granted Critical
Publication of JP5638007B2 publication Critical patent/JP5638007B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
JP2011546297A 2009-01-16 2010-01-12 ベータ−アミロイド産生の減少のための二環式化合物 Expired - Fee Related JP5638007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14531909P 2009-01-16 2009-01-16
US61/145,319 2009-01-16
PCT/US2010/020710 WO2010083141A1 (en) 2009-01-16 2010-01-12 Bicyclic compounds for the reduction of beta-amyloid production

Publications (3)

Publication Number Publication Date
JP2012515205A JP2012515205A (ja) 2012-07-05
JP2012515205A5 JP2012515205A5 (OSRAM) 2013-01-17
JP5638007B2 true JP5638007B2 (ja) 2014-12-10

Family

ID=42061022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546297A Expired - Fee Related JP5638007B2 (ja) 2009-01-16 2010-01-12 ベータ−アミロイド産生の減少のための二環式化合物

Country Status (8)

Country Link
US (1) US8349880B2 (OSRAM)
EP (1) EP2379553B1 (OSRAM)
JP (1) JP5638007B2 (OSRAM)
CN (1) CN102356081B (OSRAM)
AR (1) AR075139A1 (OSRAM)
ES (1) ES2426023T3 (OSRAM)
TW (1) TW201030002A (OSRAM)
WO (1) WO2010083141A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AU2010211109B2 (en) 2009-02-06 2014-11-27 Cellzome Limited Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
MX2011011753A (es) 2009-05-07 2011-11-29 Janssen Pharmaceuticals Inc Nuevos derivados sustitutos de indazol y aza-indazol como moduladores de la gamma secretasa.
CA2778517A1 (en) 2009-07-15 2011-01-20 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
PH12012501381A1 (en) * 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
LT2603513T (lt) 2010-08-10 2020-05-25 Takeda Pharmaceutical Company Limited Heterociklinis junginys ir jo panaudojimas kaip ampa receptoriaus teigiamo alosterinio moduliatoriaus
KR20130139895A (ko) * 2010-09-02 2013-12-23 다케다 야쿠힌 고교 가부시키가이샤 경도인지 장애의 치료 또는 예방용 융합 트리아졸
TW201309655A (zh) * 2011-01-28 2013-03-01 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
MX355164B (es) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
ES2608356T3 (es) 2012-12-20 2017-04-10 Janssen Pharmaceutica Nv Novedosos derivados tricíclicos de 3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona como moduladores de la secretasa gamma
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
PL3004079T3 (pl) 2013-06-04 2018-07-31 Acturum Real Estate Ab Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
US9718805B2 (en) 2013-06-04 2017-08-01 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN109311878B (zh) * 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
US10941147B2 (en) 2016-11-01 2021-03-09 Hoffmann-La Roche Inc. Bicyclic heteroaryl derivatives
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN111315745B (zh) * 2017-12-18 2023-07-14 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物
WO2019141832A1 (en) * 2018-01-22 2019-07-25 F. Hoffmann-La Roche Ag Triazolo-azepine derivatives
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
JP7777527B2 (ja) 2019-11-29 2025-11-28 エフ． ホフマン－ラ ロシュ アーゲー （９Ｓ）－２－ブロモ－９－（２，３，４－トリフルオロフェニル）－６，７，８，９－テトラヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］アゼピンの製造方法
CN119604488A (zh) * 2022-08-08 2025-03-11 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医疗用途
CN120324393B (zh) * 2025-05-20 2025-11-04 广东海洋大学 (2,4-二氯苯基)甲基硫基甲烷脒及其盐的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
JP5209043B2 (ja) * 2007-05-07 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼ調節剤
DE602008004769D1 (en) 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2181992B8 (en) 2007-08-31 2013-06-26 Eisai R&D Management Co., Ltd. Polycyclic compound
CN101910142B (zh) 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂

Also Published As

Publication number Publication date
US20110015175A1 (en) 2011-01-20
EP2379553A1 (en) 2011-10-26
ES2426023T3 (es) 2013-10-18
JP2012515205A (ja) 2012-07-05
AR075139A1 (es) 2011-03-09
US8349880B2 (en) 2013-01-08
WO2010083141A1 (en) 2010-07-22
CN102356081A (zh) 2012-02-15
CN102356081B (zh) 2014-08-27
EP2379553B1 (en) 2013-06-26
TW201030002A (en) 2010-08-16

Similar Documents

Publication Publication Date Title
JP5638007B2 (ja) ベータ−アミロイド産生の減少のための二環式化合物
TWI468402B (zh) 降低β－類澱粉生成之化合物
US7935815B2 (en) Imidazoyl pyridine compounds and salts thereof
US9453000B2 (en) Polycyclic compound
JP5755739B2 (ja) β−アミロイド産生の減少のための化合物
US8637525B2 (en) Compounds for the reduction of beta-amyloid production
US9365588B2 (en) Benzoxazines as modulators of ion channels
US20140171427A1 (en) Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2015138689A1 (en) Fused morpholinopyrimidines and methods of use thereof
HK1164732B (en) Compounds for the reduction of beta-amyloid production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140319

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141021

LAPS Cancellation because of no payment of annual fees